Emerging & Pipeline Therapies for Alzheimer Disease
The Alzheimer disease (AD) therapeutic landscape has undergone a paradigm shift with the approval of anti-amyloid monoclonal antibodies, yet these agents address only one component of a multifactorial disease. Beyond amyloid clearance, a robust pipeline of investigational therapies targets tau pathology, neuroinflammation, metabolic dysfunction, and genetic risk factors. Simultaneously, lessons from high-profile failures — including BACE inhibitors and gamma-secretase inhibitors — have reshaped how the field approaches drug development. As of early 2026, more than 140 agents are under investigation in approximately 190 active clinical trials, with roughly 80% targeting disease modification. This article reviews the most significant emerging therapeutic strategies, their current trial status, and the evolving frameworks for precision medicine and combination therapy in AD.
Bottom Line
- Anti-tau immunotherapy remains an active area of investigation; bepranemab reduced tau accumulation by 33–58% in Phase 2 but failed its primary clinical endpoint (CDR-SB), while etalanetug (E2814) has received FDA Fast Track designation based on promising biomarker engagement in dominantly inherited AD
- Neuroinflammation targets — including TREM2 agonists and microglial modulators — represent a growing proportion of the AD pipeline, supported by genetic evidence linking innate immune pathways to disease risk
- GLP-1 receptor agonists (semaglutide) failed primary cognitive endpoints in the Phase 3 EVOKE program despite reducing systemic inflammation; observational data suggest greater potential for prevention than treatment of established AD
- Gene therapy: LX1001 (AAV-delivered APOE2) showed dose-dependent APOE2 expression and tau biomarker reduction in APOE4 homozygotes in Phase 1/2; CRISPR-based APOE4 correction remains preclinical
- Antisense oligonucleotides targeting MAPT (BIIB080) are in Phase 2 and offer a mechanism to reduce total tau production via intrathecal delivery
- Combination therapy — pairing amyloid clearance with tau-targeting agents — is now being tested directly, with the etalanetug + lecanemab Phase 2 trial representing the first major amyloid–tau dual approach
- Lifestyle interventions have disease-modifying potential: the U.S. POINTER trial (published JAMA 2025) demonstrated that structured multidomain interventions protect cognition for up to 2 years in at-risk older adults
- Failed BACE inhibitors taught critical lessons about mechanism-based toxicity; cognitive worsening resulted from off-target cleavage of BACE1 substrates essential for synaptic function, not from amyloid reduction itself
Anti-Tau Immunotherapy
Given that tau neurofibrillary tangle burden correlates more closely with clinical severity than amyloid plaque load, tau-directed immunotherapies remain a major focus of the AD pipeline. Multiple monoclonal antibodies targeting different tau epitopes are in clinical development, though none has yet achieved FDA approval.
Bepranemab (UCB)
- Monoclonal antibody targeting the mid-region of tau, designed to intercept tau propagation between neurons
- TOGETHER Phase 2 trial (NCT04867616): enrolled patients with prodromal to mild AD over 80 weeks
- Reduced tau accumulation by 33–58% versus placebo as measured by tau mid-region biomarkers
- Primary endpoint (CDR-SB): not met — no significant difference versus placebo on clinical progression
- Secondary endpoint (ADAS-Cog): significant improvement observed, suggesting possible cognitive signal
- Results presented at CTAD 2024; further development plans under review
Etalanetug (E2814) — Eisai
- Anti-MTBR (microtubule-binding region) tau antibody targeting the seed-competent domain of tau
- Received FDA Fast Track designation in September 2025
- Phase 1b/2 data in dominantly inherited AD (DIAD) patients (n=7):
- CSF eMTBR-tau243 reduced by 62% at 3 months and 89% at 9 months
- Plasma eMTBR-tau243 reduced by 78% at 3 months, >90% at 9 months
- Tau PET signals stabilized or trended toward decrease
- Currently under investigation in the Tau NexGen Phase 2/3 trial (DIAN-TU) for dominantly inherited AD
- Phase 2 Study 202: testing etalanetug combined with lecanemab as standard of care in early sporadic AD — the first major amyloid–tau combination trial
Semorinemab (Genentech/Roche)
- IgG4 antibody targeting the N-terminus of monomeric and oligomeric tau
- Missed primary endpoint (CDR-SB) and both secondary endpoints (ADAS-Cog13, ADCS-ADL) in Phase 2
- Development discontinued for this indication
Other Anti-Tau Agents Under Investigation
- Posdinemab: Phase 2 data expected by late 2025
- BMS-986446 (Bristol Myers Squibb): Phase 2 ongoing
- MK-2214 (Merck): Phase 2 ongoing
- JNJ-63733657 (Johnson & Johnson): Phase 2
- Lu AF87908 (Lundbeck): Phase 2
- PNT001: targeting cis-phosphorylated tau (acute neuronal injury model)
Anti-Tau Therapy: Key Takeaways
- No anti-tau monoclonal antibody has met its primary clinical endpoint in AD to date
- Biomarker engagement (tau reduction in CSF and on PET) has been demonstrated by multiple agents, but this has not yet translated to consistent clinical benefit
- The discordance between biomarker response and clinical outcome may reflect the complexity of tau biology — different tau species and epitopes may have distinct pathogenic roles
- The combination approach (anti-amyloid + anti-tau) is the logical next step and is now under formal investigation
- Etalanetug is the most advanced anti-tau candidate with the strongest biomarker signal as of early 2026
Tau Aggregation Inhibitors & Tau Vaccines
Beyond passive immunotherapy, alternative strategies to reduce pathological tau include aggregation inhibitors and active immunization approaches.
- AADvac1 (Axon Neuroscience): active tau vaccine that generates endogenous anti-tau antibodies; Phase 2 completed with evidence of immunogenicity but uncertain clinical impact
- ACI-35 (AC Immune/Janssen): anti-phospho-tau vaccine targeting phosphorylated tau epitopes; Phase 2 ongoing
- Active vaccination offers potential advantages over passive immunotherapy: lower cost, less frequent dosing, and sustained immune response
- Key concern: inducing an immune response against a self-protein carries theoretical risk of autoimmune neuroinflammation, though clinical data have been reassuring to date
Neuroinflammation Targets
Genome-wide association studies have identified numerous AD risk loci in genes expressed predominantly in microglia and innate immune pathways, including TREM2, CD33, MS4A, PLCG2, and ABI3. This genetic evidence has driven a major expansion of neuroinflammation-targeting therapies in the AD pipeline.
TREM2 Agonists
- TREM2 (triggering receptor expressed on myeloid cells 2) is a microglial surface receptor that promotes phagocytosis, synaptic pruning, and containment of amyloid plaques
- Loss-of-function TREM2 variants (e.g., R47H) confer a 2–4× increased risk of AD
- TREM2 agonist antibodies aim to enhance protective microglial function around amyloid plaques
- Multiple early-phase candidates are in clinical development (Phase 1–2)
- Key challenge: achieving adequate CNS exposure for peripherally administered antibodies; brain-penetrant formulations are under investigation
Microglial Modulators & Other Targets
- CD33 inhibitors: reducing CD33 expression on microglia enhances amyloid phagocytosis in preclinical models
- NLRP3 inflammasome inhibitors: targeting the NLRP3 pathway to reduce IL-1β–mediated neuroinflammatory cascades
- Colony-stimulating factor 1 receptor (CSF1R) modulators: approaches to reprogram rather than deplete microglia
- GFAP (glial fibrillary acidic protein), a marker of astrocyte activation, is being studied both as a biomarker and as a therapeutic target; plasma GFAP is elevated early in AD and correlates with amyloid burden
Neuroinflammation: Double-Edged Sword
- Microglia play both protective and destructive roles in AD: they clear amyloid plaques and damaged synapses but can also drive chronic neuroinflammation and synapse loss
- Broad immunosuppression in the CNS carries risks of impaired pathogen defense and reduced amyloid clearance
- The therapeutic window may be stage-dependent — enhancing microglial function early in disease versus dampening neuroinflammation later
- ARIA events associated with anti-amyloid antibodies are themselves an inflammatory phenomenon, highlighting the interplay between amyloid clearance and neuroinflammation
GLP-1 Receptor Agonists
Growing epidemiological evidence has linked GLP-1 receptor agonist use in type 2 diabetes to reduced rates of incident dementia, prompting dedicated clinical trials in AD. Proposed mechanisms include anti-inflammatory effects, vascular protection, improved insulin signaling, and direct neuroprotection through GLP-1 receptors expressed on neurons and microglia.
Semaglutide: EVOKE Trial Program
- EVOKE and EVOKE+ (Novo Nordisk): Phase 3 trials of oral semaglutide in early symptomatic AD
- Double-blind, placebo-controlled design; main phase completion in 2025
- Results presented at CTAD 2025:
- Semaglutide was well-tolerated with a safety profile consistent with known GI side effects
- Did NOT demonstrate superiority over placebo on cognitive outcomes
- Failed primary endpoints
- Plasma high-sensitivity CRP decreased by ~30% with treatment, confirming systemic anti-inflammatory effect
- 52-week extension phase ongoing through October 2026
Liraglutide: ELAD Trial
- Phase 2b trial (N=204) in mild-to-moderate AD without diabetes; daily liraglutide injections for 52 weeks
- Published in Nature Medicine 2025
- Safe and well-tolerated but did not significantly slow brain metabolism decline (primary endpoint)
GLP-1 Receptor Agonists in AD: Current Status
- No GLP-1 RA is FDA-approved for AD treatment
- Clinical trial results in established AD (EVOKE, ELAD) have been disappointing
- Observational data remain compelling: GLP-1RA use in diabetes is associated with a ~70% reduced risk of incident dementia compared with non-GLP-1RA antidiabetics
- The discrepancy suggests GLP-1 RAs may have greater potential for prevention than for treatment of established AD
- Further prevention-focused trials are anticipated based on the strength of observational evidence
Gene Therapy Approaches
Gene therapy offers the potential for durable, single-administration disease modification by directly altering the genetic risk architecture of AD. The most advanced programs target APOE4, the strongest common genetic risk factor for sporadic AD.
LX1001 — APOE4 Gene Therapy (Lexeo Therapeutics)
- Adeno-associated viral (AAV) vector delivering the APOE2 gene into the CNS of APOE4 homozygotes
- Goal: convert the APOE profile from E4/E4 to E2/E4, conferring a protective allelic shift
- Phase 1/2 trial (NCT03634007) results presented at CTAD 2024:
- Generally safe and well-tolerated; no ARIA reported
- Dose- and time-dependent APOE2 expression detected in CSF
- CSF t-tau and p-tau181 decreased in 9 of 13 participants
- CSF p-tau217 and p-tau231 also decreased in the same patients
- Tau PET changes suggested treatment effect on tau pathology
CRISPR/Cas9 & Other Approaches
- CRISPR-based APOE4 → APOE3 editing: explored in preclinical models; could directly correct the risk allele rather than adding a protective one
- As of March 2025, at least 25 NIH-funded gene therapy candidates are in human trials (18 Phase 1, 7 Phase 2/3)
- Multiple approaches under development: gene replacement, gene silencing, and gene editing
- Key challenges remain: reliable delivery across the blood-brain barrier, long-term durability, and comprehensive safety monitoring
Antisense Oligonucleotides (ASOs)
Antisense oligonucleotides provide a mechanistically distinct approach to tau reduction by targeting MAPT mRNA to prevent tau protein production at the translational level, rather than clearing already-formed tau aggregates.
- BIIB080 (Ionis/Biogen): tau-lowering ASO administered by intrathecal injection
- Reduces total tau protein production by degrading MAPT mRNA
- Phase 1 data demonstrated dose-dependent reductions in CSF total tau and phospho-tau
- Phase 2 trials ongoing
- Advantages: directly reduces tau production upstream of aggregation; does not require CNS penetration from the periphery
- Limitations: requires repeated lumbar puncture for intrathecal dosing (typically every 4–12 weeks); long-term safety data limited
Synaptic & Neurotransmitter Approaches Beyond Cholinergic Targets
While acetylcholinesterase inhibitors remain the backbone of symptomatic AD therapy, novel neurotransmitter and synaptic approaches aim to address additional mechanisms of cognitive decline.
- Muscarinic M1 receptor agonists: selective activation of postsynaptic M1 receptors may enhance cognition without peripheral cholinergic side effects; several candidates in early clinical trials
- 5-HT6 receptor antagonists: promote cortical glutamate and acetylcholine release; previous candidates (idalopirdine, intepirdine) failed Phase 3 but newer agents are being explored
- Sigma-1 receptor agonists: modulate endoplasmic reticulum stress and calcium signaling; blarcamesine (ANAVEX2-73) in Phase 2/3
- Synaptic vesicle glycoprotein 2A (SV2A) modulators: targeting synaptic function directly; SV2A PET is being explored as a biomarker of synaptic density
- Orexin receptor antagonists: suvorexant is FDA-approved for insomnia in AD; ongoing research into whether improving sleep architecture may reduce amyloid accumulation
Combination Therapy Strategies
The multifactorial nature of AD pathogenesis supports the rationale for combination approaches, analogous to oncology paradigms where single-target therapies are rarely curative.
- Amyloid clearance + anti-tau: the etalanetug + lecanemab Phase 2 trial is the first formal test of this dual approach in sporadic AD
- Amyloid clearance + symptomatic therapy: lecanemab and donanemab are intended to be used alongside acetylcholinesterase inhibitors and memantine
- Amyloid clearance + neuroinflammation modulation: conceptually attractive given that ARIA itself reflects an inflammatory response to amyloid mobilization
- Sequential therapy: donanemab's unique finite-dosing model (treatment stops once amyloid is cleared) creates a natural framework for sequential addition of tau-targeting or neuroprotective agents
| Pipeline Category | Agent | Mechanism | Phase | Key Findings / Status |
|---|---|---|---|---|
| Anti-Tau Antibody | Bepranemab | Mid-region tau | Phase 2 | Tau reduction 33–58%; CDR-SB not met; ADAS-Cog significant |
| Anti-Tau Antibody | Etalanetug (E2814) | MTBR tau | Phase 2/3 | FDA Fast Track; CSF tau ↓89% at 9 months; combo trial with lecanemab |
| Anti-Tau Antibody | Semorinemab | N-terminal tau | Phase 2 | Failed primary & secondary endpoints; discontinued |
| Tau Vaccine | AADvac1 | Active immunization | Phase 2 | Immunogenic; uncertain clinical impact |
| Tau ASO | BIIB080 | MAPT mRNA degradation | Phase 2 | Dose-dependent CSF tau reduction; intrathecal delivery |
| GLP-1 RA | Semaglutide (oral) | GLP-1 receptor agonism | Phase 3 | EVOKE: failed primary endpoints; CRP ↓30% |
| Gene Therapy | LX1001 | AAV-APOE2 delivery | Phase 1/2 | APOE2 expression in CSF; tau biomarkers decreased |
| Anti-Amyloid (next-gen) | Remternetug | SC anti-pyroglutamated Aβ | Phase 3 | 75% reached amyloid clearance by day 169; SC self-administration |
| Anti-Amyloid (next-gen) | Trontinemab | BBB-crossing anti-Aβ | Phase 2 | Brainshuttle technology; effective clearance with low side effects |
| Neuroinflammation | TREM2 agonists (multiple) | Enhanced microglial function | Phase 1–2 | Preclinical promise; CNS penetration remains a challenge |
Lifestyle Interventions: U.S. POINTER Trial
The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) represents the first large-scale American trial to demonstrate that accessible, community-based multidomain lifestyle interventions can protect cognition in older adults at risk for cognitive decline.
- Published in JAMA, July 28, 2025 (simultaneous with AAIC 2025 presentation)
- N=2,111 participants; ages 60–79 years; 5 US sites; 2-year randomized clinical trial
- Compared structured (STR) versus self-guided (SG) lifestyle interventions targeting: physical exercise, nutrition, cognitive/social engagement, and cardiovascular health monitoring
- Both groups improved cognition, but the structured intervention showed significantly greater improvement on global cognition
- Cognitive function was protected from normal age-related decline for up to 2 years
- Demonstrated benefit in a racially and ethnically diverse population
- Modeled on the landmark Finnish FINGER trial, adapted for US community settings
Precision Medicine & Biomarker-Guided Treatment Selection
The emergence of blood-based biomarkers, expanded PET imaging capabilities, and refined genetic profiling is enabling an increasingly personalized approach to AD therapeutics.
- APOE genotyping guides ARIA risk stratification: E4 homozygotes face the highest risk (ARIA-E up to 34–42%) and require the most intensive MRI monitoring
- Tau PET staging informs prognosis and may predict response to therapy: donanemab showed greater efficacy in patients with low/medium versus high tau burden
- Plasma p-tau217 (FDA-cleared May 2025) enables screening-level AD diagnosis in primary care settings, potentially transforming the patient identification funnel
- The 2024 AA revised criteria formally define AD as a biological process diagnosed by biomarkers, enabling treatment at the earliest detectable stages
- Emerging two-cutoff approach for plasma biomarkers: patients clearly above or below thresholds can avoid confirmatory PET/CSF testing, reducing cost and invasiveness
| Factor | Clinical Application | Treatment Implication |
|---|---|---|
| APOE genotype | ARIA risk assessment | E4/E4: higher ARIA risk; intensive MRI monitoring; shared decision-making |
| Tau PET (Braak staging) | Biological disease staging | Low/medium tau: better response to donanemab; high tau: consider combination therapy |
| Plasma p-tau217 | Screening and diagnosis | Triage tool before PET/CSF; enables earlier treatment initiation |
| Amyloid PET (centiloids) | Treatment monitoring | Donanemab: treatment can stop once clearance thresholds (<11 CL) are met |
| Baseline MRI (microbleeds) | Safety assessment | >4 microhemorrhages or superficial siderosis: relative contraindication to anti-amyloid Rx |
| Anticoagulant use | Bleeding risk with ARIA-H | Anticoagulants generally contraindicated with anti-amyloid therapy |
Lessons from Failed Trials
The AD drug development field has experienced a historically high failure rate, with some of the most instructive lessons arising from the BACE inhibitor and gamma-secretase inhibitor programs.
BACE Inhibitor Failures
- Verubecestat (Merck): EPOCH trial in mild-to-moderate AD — no clinical benefit; increased adverse effects including psychiatric symptoms
- Atabecestat (Janssen/Shionogi): Phase 2/3 terminated for liver toxicity
- Lanabecestat (AstraZeneca/Eli Lilly): Phase 3 discontinued for futility
- Umibecestat (Novartis): API Generation prevention studies — cognitive worsening observed (reversible upon drug washout)
- Elenbecestat (Eisai/Biogen): Phase 3 stopped due to unfavorable risk-benefit ratio
Key Lessons from BACE Inhibitor & Gamma-Secretase Inhibitor Failures
- Mechanism-based toxicity: BACE1 cleaves multiple substrates beyond APP, including neuregulin-1, seizure-related gene 6, and CHL1, which are critical for synaptic plasticity; broad BACE1 inhibition caused cognitive worsening through off-target effects
- Production inhibition ≠ plaque clearance: reducing new amyloid production does not remove existing plaques, whereas monoclonal antibodies actively clear deposited amyloid — a fundamental mechanistic distinction
- Dose-toxicity dilemma: achieving meaningful Aβ reduction required very high BACE1 inhibition (≥90% to reduce Aβ by ~50% in preclinical models), but these doses maximized off-target toxicity
- Timing matters: inhibiting amyloid production may be insufficient once extensive plaque deposition has already occurred
- Gamma-secretase inhibitors (e.g., semagacestat) similarly failed due to nonselective cleavage of Notch and other substrates, causing gastrointestinal toxicity and paradoxical cognitive worsening
- Reversibility finding: cognitive decline with umibecestat was not dose-dependent and reversed after washout, suggesting a pharmacologic rather than neurodegenerative mechanism
Future Directions
- Prevention trials: the AHEAD Study (lecanemab in preclinical amyloid-positive individuals) and TRAILBLAZER-ALZ 3 (donanemab in preclinical AD) have completed enrollment and will define whether early intervention can prevent symptom onset
- Next-generation anti-amyloid agents: remternetug (subcutaneous, higher-affinity donanemab successor) and trontinemab (BBB-crossing Brainshuttle technology) aim to improve convenience and CNS penetration
- Combination designs: the etalanetug + lecanemab trial is the prototype; future combination regimens may add neuroinflammation modulators or neuroprotective agents
- Blood biomarker–guided screening: FDA-cleared plasma p-tau217 testing will democratize AD diagnosis beyond specialty memory clinics, identifying treatment-eligible patients earlier
- Health equity: ensuring that underserved populations — who are diagnosed at more advanced stages and have lower access to specialty diagnostics — benefit from therapeutic advances remains a critical priority
References
- Cummings J, Zhou Y, Lee G, et al. Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2):e12385.
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.
- Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527.
- Geldmacher DS. Treatment of Alzheimer disease. Continuum (Minneap Minn). 2024;30(6, Dementia):1823-1844.
- Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20:5143-5169.
- UCB. Bepranemab Phase 2 TOGETHER trial results. Presented at: CTAD 2024; Madrid, Spain.
- Eisai. Etalanetug (E2814) Phase 1b/2 data in dominantly inherited Alzheimer's disease. Presented at: CTAD December 2025.
- Novo Nordisk. Semaglutide EVOKE and EVOKE+ Phase 3 trial results. Presented at: CTAD 2025.
- Edison P, Femminella GD, Ritchie CW, et al. Liraglutide in Alzheimer's disease: the ELAD Phase 2b trial. Nat Med. 2025.
- Lexeo Therapeutics. LX1001 APOE4 gene therapy Phase 1/2 results. Presented at: CTAD 2024; Madrid, Spain.
- Baker LD, Espeland MA, Kivipelto M, et al; U.S. POINTER Investigators. Multidomain lifestyle intervention to protect brain health in older adults: U.S. POINTER randomized clinical trial. JAMA. 2025.
- Ngandu T, Lehtisalo J, Solomon A, et al. A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263.
- Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med. 2018;378(18):1691-1703.
- Henley D, Raghavan N, Sperling R, et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease. N Engl J Med. 2019;380(15):1483-1485.
- Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377.
- Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized Phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9(2):197-210.
- Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384(18):1691-1704.
- Teng E, Manser PT, Pickthorn K, et al. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022;79(8):758-767.